The estimated Net Worth of Francisco Diaz Mitoma is at least $925 Tisíc dollars as of 30 September 2019. Francisco Mitoma owns over 54,500 units of VBI Vaccines stock worth over $8,225 and over the last 8 years he sold VBIV stock worth over $0. In addition, he makes $917,198 as Chief Medical Officer at VBI Vaccines.
Francisco has made over 6 trades of the VBI Vaccines stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 54,500 units of VBIV stock worth $27,250 on 30 September 2019.
The largest trade he's ever made was buying 54,500 units of VBI Vaccines stock on 30 September 2019 worth over $27,250. On average, Francisco trades about 8,531 units every 48 days since 2017. As of 30 September 2019 he still owns at least 117,500 units of VBI Vaccines stock.
You can see the complete history of Francisco Mitoma stock trades at the bottom of the page.
Dr. Francisco Diaz-Mitoma M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Diaz-Mitoma has served as our Chief Medical Officer since February 2016 through his medical professional services corporation. He is a board-certified medical microbiologist and medical scientist who most recently served as a professor of the Northern Ontario School of Medicine (“NOSM”). While in this position, Dr. Diaz-Mitoma was Vice President of Research at Health Sciences North and founder of the Advanced Medical Research Institute of Canada (“AMRIC”) and served as its Chief Executive Officer, Chief Scientist and board secretary from June 2011 to November 2015. AMRIC (now known as Health Sciences North Research Institute) is focused on translational medical and vaccine development research. From June 2011 to November 2015 he was also a board member of the Northern Ontario Cancer Foundation. Prior to joining the faculty at the NOSM, Dr. Diaz-Mitoma was a professor of Pediatrics, Pathology, Laboratory Medicine, and Microbiology at the University of Ottawa. While in this position, he founded the Vaccine and Infectious Disease Centre at the Children’s Hospital of Eastern Ontario (“CHEO”), a pediatric health and research center. Dr. Diaz-Mitoma received his medical degree from the University of Guadalajara, completed fellowship training in Infectious Diseases at the University of Manitoba, and earned a Ph.D. in Virology from the University of Alberta. Dr. Diaz-Mitoma has also served as a director of Bowhead Health, Inc., a Medical device and medical data management Canadian company since January 2016.
As the Chief Medical Officer of VBI Vaccines, the total compensation of Francisco Mitoma at VBI Vaccines is $917,198. There are 2 executives at VBI Vaccines getting paid more, with Jeffrey Baxter having the highest compensation of $1,379,630.
Francisco Mitoma is 65, he's been the Chief Medical Officer of VBI Vaccines since 2016. There are 3 older and 16 younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.
Francisco's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv a Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.
vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
VBI Vaccines executives and other stock owners filed with the SEC include: